logo-loader

IXICO CTO on IXI platform upgrade, AI and expanding technology partnerships

Published: 06:30 19 Nov 2026 EST

IXICO PLC (LSE:IXI, OTC:PHYOF) chief technology officer Mark Austin talked with Proactive's Stephen Gunnion about the latest upgrade to its IXI platform, expanding technology partnerships and the growing role of artificial intelligence (AI) in neurological drug development.

Austin explained how improved infrastructure, scalability and application programming interfaces (APIs) will help pharmaceutical customers manage brain imaging data more efficiently, accelerate clinical trial deployment and access results sooner.

The upgrade also advances IXICO's techbio strategy, with IXI offering potential licensing opportunities and new annual recurring revenue streams. The platform recently won Technology Innovation of the Year at the Citeline Biotech Awards.

Austin also discussed collaborations involving advanced imaging algorithms and specialist PET analysis, which could expand the company's capabilities in Parkinson's and Alzheimer's disease research.

He highlighted AI's potential to detect subtle changes in disease progression more accurately, potentially enabling shorter clinical trials with fewer patients and earlier decisions on treatment effectiveness.

Looking ahead, IXICO aims to combine MRI, PET, fluid biomarkers and clinical data to build a more complete picture of neurological disease. Austin also explained how generative AI is accelerating internal platform development and supporting the company's wider ambitions.

For more interviews and updates on healthcare innovation, biotechnology and drug development, visit Proactive's YouTube channel. Don't forget to like this video, subscribe to the channel and enable notifications for future content.

Read Proactive’s Editorial Policy here.

#IXICO #ArtificialIntelligence #DrugDevelopment #ClinicalTrials #Biotechnology #NeurodegenerativeDiseases #MedicalImaging #ImagingBiomarkers #AlzheimersDisease #ParkinsonsDisease #AIinHealthcare #PharmaceuticalResearch #TechBio #MRI #PETImaging

IXICO lands £2.7m Huntington’s disease trial contract, second win in a year...

IXICO PLC (LSE:IXI, OTC:PHYOF, FRA:PYPB) has secured a £2.7 million contract for a phase three Huntington’s disease clinical trial, marking its second contract in the field in 12 months. Chief executive Bram Goorden said the latest award would provide the medical imaging company with greater...

1 week, 5 days ago